In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 years of age who had preexisting or a high risk of cardiovascular disease and who ...
As new therapies improve survival from cancer, attention to comorbid illness and complications of therapy—both short- and long-term—become much more important to improving not only quality of life but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results